Sun Lihua, Wang Juan, Yan Xiafeng, Wei Shumin, Zhang Kui
Emergency Department, Dongying People's Hospital Dongying 257000, Shandong, China.
Cardiovascular Medicine Department, Dongying People's Hospital Dongying 257000, Shandong, China.
Am J Transl Res. 2024 Nov 15;16(11):6812-6820. doi: 10.62347/WMBN8994. eCollection 2024.
To investigate the effect of Danlou tablets combined with aspirin for treating phlegm and blood stasis syndrome in coronary heart disease (CHD).
This study is a retrospective study, a total of 120 patients with phlegm and blood stasis syndrome with CHD were randomly assigned to either a control group (aspirin, 100 mg, once daily) or an observation group (Danlou tablets, 1.5 g, three times daily; aspirin, 100 mg, once daily) at a 1:1 ratio. Treatment was administered for 28 consecutive days. Pre- and post-treatment assessments included lipid profiles, hemorheology, inflammatory markers, serum phospholipase A2 (sPLA), lipoprotein-associated phospholipase 2 (LP-PLA), oxidized low-density lipoprotein (ox-LDL), monocyte chemotactic protein-1 (MCP-1), clinical efficacy, adverse events, and changes in TCM syndrome scores.
After 1 month of treatment, the observation group showed a significantly higher overall clinical efficacy rate (P = 0.038) compared to the control group. Post-treatment levels of sPLA, LP-PLA, ox-LDL, and MCP-1 decreased in both groups, with significantly lower levels in the observation group (P = 0.001, P = 0.013, P = 0.015). Additionally, reductions in small dense low-density lipoprotein cholesterol (sdLDL-C), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), fibrinogen, erythrocyte volume, tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) were significantly greater in the observation group than in the control group (P = 0.023, P = 0.023, P = 0.014, P = 0.012, P = 0.032, P = 0.019, P = 0.030).
The combination of Danlou tablets and aspirin significantly improves clinical symptoms in CHD patients with phlegm and blood stasis syndrome, reduces serum sPLA, LP-PLA, and ox-LDL levels, and inhibits inflammatory responses, suggesting this combination could provide a beneficial adjunctive therapy for managing CHD in these patients. This study serves as a reference for further research on Danlou tablets' role in CHD.
探讨丹蒌片联合阿司匹林治疗冠心病（CHD）痰瘀证的效果。
本研究为回顾性研究，将120例CHD痰瘀证患者按1:1比例随机分为对照组（阿司匹林，100mg，每日1次）和观察组（丹蒌片，1.5g，每日3次；阿司匹林，100mg，每日1次）。连续治疗28天。治疗前后评估指标包括血脂谱、血液流变学、炎症标志物、血清磷脂酶A2（sPLA）、脂蛋白相关磷脂酶2（LP-PLA）、氧化型低密度脂蛋白（ox-LDL）、单核细胞趋化蛋白-1（MCP-1）、临床疗效、不良事件及中医证候评分变化。
治疗1个月后，观察组总体临床有效率显著高于对照组（P = 0.038）。两组治疗后sPLA、LP-PLA、ox-LDL和MCP-1水平均下降，观察组水平显著更低（P = 0.001，P = 0.013，P = 0.015）。此外，观察组小而密低密度脂蛋白胆固醇（sdLDL-C）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、纤维蛋白原、红细胞体积、肿瘤坏死因子-α（TNF-α）和白细胞介素-6（IL-6）的降低幅度显著大于对照组（P = 0.023，P = 0.023，P = 0.014，P = 0.012，P = 0.032，P = 0.019，P = 0.030）。
丹蒌片联合阿司匹林可显著改善CHD痰瘀证患者的临床症状，降低血清sPLA、LP-PLA和ox-LDL水平，抑制炎症反应，提示该联合用药可为这些患者的CHD治疗提供有益的辅助治疗。本研究为进一步研究丹蒌片在CHD中的作用提供参考。
